Vorinostat (rINN) also known as suberanilohydroxamic acid is a member of a
larger class of compounds that inhibit histone deacetylases (HDAC).
Results of animal studies indicate that vorinostat crosses the placenta and is
found in fetal plasma at levels up to 50% of maternal concentrations. Doses.
Aug 15, 2016 ... Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in
people whose disease has not improved, has gotten worse, ...
Suberoylanilide Hydroxamic Acid is a synthetic hydroxamic acid derivative with
antineoplastic activity. Vorinostat, a second generation polar-planar compound, ...
SAHA or Vorinostat facilitates the transcription of genes that result in apoptosis,
differentiation and growth arrest. It has been observed to give beneficial results ...
Oct 10, 2006 ... This page contains brief information about vorinostat and a collection of links to
more information about the use of this drug, research results, ...
Jul 3, 2013 ... On October 6, 2006, the U.S. Food and Drug Administration granted approval to
vorinostat (Zolinza™, Merck & Co., Inc.), a histone deacetylase ...
Dec 12, 2006 ... Vorinostat (suberoylanilide hydroxamic acid or SAHA) is a nanomolar inhibitor of
HDAC activity that has undergone initial evaluation in multiple ...
Vorinostat is a white to light orange powder. It is very slightly soluble in water,
slightly soluble in ethanol, isopropanol and acetone, freely soluble in dimethyl ...
Pharmacology. Vorinostat is a member of the hydroxamic acid subclass of
histone deacetylase (HDAC) inhibitors. Its primary biochemical mechanism is to ...